波兰高细胞遗传风险浆细胞骨髓瘤患者的优化治疗

Q4 Medicine

Hematologia Pub Date : 2022-10-20 DOI:10.5603/hcp.a2022.0007

K. Giannopoulos, K. Jamroziak, T. Wróbel, D. Dytfeld

{"title":"波兰高细胞遗传风险浆细胞骨髓瘤患者的优化治疗","authors":"K. Giannopoulos, K. Jamroziak, T. Wróbel, D. Dytfeld","doi":"10.5603/hcp.a2022.0007","DOIUrl":null,"url":null,"abstract":"Plasma cell myeloma (PCM) is a hematologic malignancy that derives from mature B cells. The prognosis of patients with PCM is highly dependent on the presence of cytogenetic aberrations. Determination of cytogenetic risk enables informing patients about their prognosis and allows for individual choice of therapy. In Poland, cytogenetic risk assessment is a fully reimbursed procedure, and it is recommended to perform such an examination in every diagnosed patient. Therapy of patients with high cytogenetic risk should be planned with consideration of tandem autotrans-plantation of hematopoietic cells in eligible patients. In patients with refractory or relapsed PCM, treatment with ixazomib in combination with lenalidomide and dexamethasone appears to remove cytogenetic risk.","PeriodicalId":38988,"journal":{"name":"Hematologia","volume":"80 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Optimization of treatment of patients with plasma cell myeloma with high cytogenetic risk in Poland\",\"authors\":\"K. Giannopoulos, K. Jamroziak, T. Wróbel, D. Dytfeld\",\"doi\":\"10.5603/hcp.a2022.0007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Plasma cell myeloma (PCM) is a hematologic malignancy that derives from mature B cells. The prognosis of patients with PCM is highly dependent on the presence of cytogenetic aberrations. Determination of cytogenetic risk enables informing patients about their prognosis and allows for individual choice of therapy. In Poland, cytogenetic risk assessment is a fully reimbursed procedure, and it is recommended to perform such an examination in every diagnosed patient. Therapy of patients with high cytogenetic risk should be planned with consideration of tandem autotrans-plantation of hematopoietic cells in eligible patients. In patients with refractory or relapsed PCM, treatment with ixazomib in combination with lenalidomide and dexamethasone appears to remove cytogenetic risk.\",\"PeriodicalId\":38988,\"journal\":{\"name\":\"Hematologia\",\"volume\":\"80 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5603/hcp.a2022.0007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/hcp.a2022.0007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

摘要

浆细胞骨髓瘤(PCM)是一种源自成熟B细胞的血液恶性肿瘤。PCM患者的预后高度依赖于细胞遗传畸变的存在。细胞遗传学风险的确定可以使患者了解其预后，并允许个体选择治疗。在波兰，细胞遗传学风险评估是一项全额报销的程序，建议对每一位确诊的患者进行这样的检查。对于细胞遗传风险高的患者，应考虑在符合条件的患者中进行串联自体造血细胞移植。在难治性或复发性PCM患者中，依沙唑米联合来那度胺和地塞米松治疗似乎可以消除细胞遗传学风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Optimization of treatment of patients with plasma cell myeloma with high cytogenetic risk in Poland

Plasma cell myeloma (PCM) is a hematologic malignancy that derives from mature B cells. The prognosis of patients with PCM is highly dependent on the presence of cytogenetic aberrations. Determination of cytogenetic risk enables informing patients about their prognosis and allows for individual choice of therapy. In Poland, cytogenetic risk assessment is a fully reimbursed procedure, and it is recommended to perform such an examination in every diagnosed patient. Therapy of patients with high cytogenetic risk should be planned with consideration of tandem autotrans-plantation of hematopoietic cells in eligible patients. In patients with refractory or relapsed PCM, treatment with ixazomib in combination with lenalidomide and dexamethasone appears to remove cytogenetic risk.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Hematologia Medicine-Oncology

自引率

0.00%

发文量

审稿时长

4 weeks

期刊介绍： Hematology is the quarterly under auspices of the Institute of Hematology and Transfusion Medicine. The journal is addressed to hematologists, oncologists and also internists. It contains the overview/review articles, case reports, essays, including reports from the scientific and educational conferences as well as test questions on hematology. Journal of the Institute of Hematology and Transfusiology.